Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 20/20 | 0.96 |
| ▸ | NSD2 | O96028 | 1/20 | 0.83 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.83 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.83 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.83 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.83 |
| ▸ | BID | P55957 | 1/20 | 0.83 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.83 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.83 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.83 |
| ▸ | ASPH | Q12797 | 1/20 | 0.83 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.83 |
| ▸ | BAD | Q92934 | 1/20 | 0.83 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.83 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1699862 | 1.00 | BCL2 (0.96) | BCL2NSD2ADORA3CYP2C9ADRA2C | |
| SCHEMBL1699863 | 1.00 | BCL2 (0.96) | BCL2NSD2ADORA3CYP2C9ADRA2C | |
| SCHEMBL30313988 | 0.98 | BCL2 (1.00) | BCL2NSD2ADORA3CYP2C9ADRA2C | |
| SCHEMBL1701506 | 0.98 | BCL2 (1.00) | BCL2NSD2ADORA3CYP2C9ADRA2C | |
| SCHEMBL1701573 | 0.98 | BCL2 (1.00) | BCL2NSD2ADORA3CYP2C9ADRA2C | |
| SCHEMBL30313963 | 0.98 | BCL2 (1.00) | BCL2NSD2ADORA3CYP2C9ADRA2C | |
| SCHEMBL31344613 | 0.98 | BCL2 (1.00) | BCL2NSD2ADORA3CYP2C9ADRA2C | |
| SCHEMBL1701508 | 0.98 | BCL2 (1.00) | BCL2NSD2ADORA3CYP2C9ADRA2C | |
| SCHEMBL30314031 | 0.98 | BCL2 (1.00) | BCL2NSD2ADORA3CYP2C9ADRA2C | |
| SCHEMBL1700667 | 0.98 | BCL2 (1.00) | BCL2NSD2ADORA3CYP2C9ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4682148-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2026-01-21 | — | — | EP | disclosed |
| EP-4474383-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2024-12-11 | — | — | EP | disclosed |
| EP-2435432-B3 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE IRELAND UNLIMITED CO (BM) | 2023-10-25 | — | — | EP | disclosed |
| EP-4243857-A1 | COMBINATION THERAPIES WITH CHIMERIC ANTIGEN RECEPTOR (CAR)-EXPRESSING CELLS | Novartis AG (CH) | 2023-09-20 | — | — | EP | disclosed |
| EP-4218731-A2 | MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | AbbVie Ireland Unlimited Company (IE) | 2023-08-02 | — | — | EP | disclosed |
| US-20230143532-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| WO-2022104061-A1 | COMBINATION THERAPIES WITH CHIMERIC ANTIGEN RECEPTOR (CAR)-EXPRESSING CELLS | NOVARTIS AG (CH) | 2022-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143532-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | BCL2 1/4885NSD2 2463/4885ADORA3 4652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.